董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Willard Dere | 男 | Lead Independent Director | 71 | 10.29万美元 | 18.15 | 2025-04-14 |
| Juergen Eckhardt | 男 | Director | 58 | 8.54万美元 | 13.02 | 2025-04-14 |
| Brian C. Thomas | 男 | Co-Founder, Chief Executive Officer, Chair of the Board and Director | 56 | 140.27万美元 | 304.40 | 2025-04-14 |
| Jian Irish | 女 | President, Chief Operating Officer and Director | 61 | 166.79万美元 | 99.99 | 2025-04-14 |
| Eric Bjerkholt | 男 | Director | 65 | 未披露 | 未持股 | 2025-04-14 |
| Eric Bjerkholt | 男 | Director | 65 | 14.68万美元 | 4.36 | 2025-04-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sarah Noonberg | 女 | Chief Medical Officer | 57 | 185.43万美元 | 未持股 | 2025-04-14 |
| Brian C. Thomas | 男 | Co-Founder, Chief Executive Officer, Chair of the Board and Director | 56 | 140.27万美元 | 304.40 | 2025-04-14 |
| Jian Irish | 女 | President, Chief Operating Officer and Director | 61 | 166.79万美元 | 99.99 | 2025-04-14 |
| Pamela Wapnick | 女 | Chief Financial Officer | 59 | 93.50万美元 | 45.72 | 2025-04-14 |
| Matthew L. Wein | 男 | Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary | 54 | 75.64万美元 | 8.29 | 2025-04-14 |
董事简历
中英对照 | 中文 | 英文- Willard Dere
-
Willard Dere，医学博士，自2016年10月起担任我们的董事之一。Dere博士担任内科教授；B.Lue和Hope S.Bettilyon担任糖尿病研究内科主席，个性化健康执行董事，犹他大学健康科学中心临床和转化科学中心的联合首席研究员。在2014年11月重新加入学术界之前，Dere博士在生物制药行业工作了25年。他于2003年加入Amgen公司，在那里他曾担任多种职务，包括全球开发、国际研究与开发主管，以及公司和国际首席医疗官。他曾领导Prolia公司的开发计划和其他几个计划，并于2014年10月退任Amgen公司。他的职业生涯始于1989年任职Eli Lilly公司，并在临床药理学、监管事务以及早期转化和后期临床研究中担任多种不同的全球职务。任职Eli Lilly公司期间，他曾领导Evista and Forteo公司的开发。Dere博士目前在RadiusHealth，Inc.董事会任职。纳斯达克市场代码:RDUS和Biomarin PharmaceuticalInc.（纳斯达克市场代码:BMRN），并担任加州再生医学研究所的科学顾问委员会成员。此前，Dere博士在犹他大学（University of Utah）的教员中任职四年，是美国医师学院（American College of Physicians）的研究员。Dere博士在加州大学戴维斯分校（University of California，Davis）获得工商管理硕士学位。
Willard Dere,has served on board of directors since August 2021 and as lead independent director since November 2024. Dr. Dere currently serves as Chief Advisor and Chief Medical Officer at Angitia since July 2022, and on the board of directors of BioMarin, Seres and Mersana. From November 2014 to August 2022 he served as a director at Radius Health. He also serves on the Scientific Advisory Boards of Surrozen, AliveGen and Heranova Lifesciences. Dr. Dere served as a Professor of Internal Medicine from November 2014 to July 2022 at the University of Utah School of Medicine, and is currently Professor Emeritus, a position he has held since July 2022. Dr. Dere also served as Associate Vice President for Research, Co-Director of The Center for Genomic Medicine and Co-Director of the Utah Clinical and Translational Science Institute at the University of Utah Health Sciences Center during this time period. Before joining the University of Utah, Dr. Dere held various positions at Amgen, Inc., including Senior Vice President of Global Development and Corporate, then International Chief Medical Officer, from July 2003 to October 2014. From 1989 to 2003, Dr. Dere held multiple positions in clinical research, and regulatory affairs and safety at Eli Lilly and Company. He was also an assistant professor from 1989 to 1999 and a clinical associate professor from 1999 to 2009 at the Indiana University School of Medicine. Dr. Dere received his B.A. in history, zoology and M.D. from the University of California, Davis; he completed his postdoctoral training at the University of Utah in internal medicine, and at the University of California, San Francisco in endocrinology and metabolism. - Willard Dere，医学博士，自2016年10月起担任我们的董事之一。Dere博士担任内科教授；B.Lue和Hope S.Bettilyon担任糖尿病研究内科主席，个性化健康执行董事，犹他大学健康科学中心临床和转化科学中心的联合首席研究员。在2014年11月重新加入学术界之前，Dere博士在生物制药行业工作了25年。他于2003年加入Amgen公司，在那里他曾担任多种职务，包括全球开发、国际研究与开发主管，以及公司和国际首席医疗官。他曾领导Prolia公司的开发计划和其他几个计划，并于2014年10月退任Amgen公司。他的职业生涯始于1989年任职Eli Lilly公司，并在临床药理学、监管事务以及早期转化和后期临床研究中担任多种不同的全球职务。任职Eli Lilly公司期间，他曾领导Evista and Forteo公司的开发。Dere博士目前在RadiusHealth，Inc.董事会任职。纳斯达克市场代码:RDUS和Biomarin PharmaceuticalInc.（纳斯达克市场代码:BMRN），并担任加州再生医学研究所的科学顾问委员会成员。此前，Dere博士在犹他大学（University of Utah）的教员中任职四年，是美国医师学院（American College of Physicians）的研究员。Dere博士在加州大学戴维斯分校（University of California，Davis）获得工商管理硕士学位。
- Willard Dere,has served on board of directors since August 2021 and as lead independent director since November 2024. Dr. Dere currently serves as Chief Advisor and Chief Medical Officer at Angitia since July 2022, and on the board of directors of BioMarin, Seres and Mersana. From November 2014 to August 2022 he served as a director at Radius Health. He also serves on the Scientific Advisory Boards of Surrozen, AliveGen and Heranova Lifesciences. Dr. Dere served as a Professor of Internal Medicine from November 2014 to July 2022 at the University of Utah School of Medicine, and is currently Professor Emeritus, a position he has held since July 2022. Dr. Dere also served as Associate Vice President for Research, Co-Director of The Center for Genomic Medicine and Co-Director of the Utah Clinical and Translational Science Institute at the University of Utah Health Sciences Center during this time period. Before joining the University of Utah, Dr. Dere held various positions at Amgen, Inc., including Senior Vice President of Global Development and Corporate, then International Chief Medical Officer, from July 2003 to October 2014. From 1989 to 2003, Dr. Dere held multiple positions in clinical research, and regulatory affairs and safety at Eli Lilly and Company. He was also an assistant professor from 1989 to 1999 and a clinical associate professor from 1999 to 2009 at the Indiana University School of Medicine. Dr. Dere received his B.A. in history, zoology and M.D. from the University of California, Davis; he completed his postdoctoral training at the University of Utah in internal medicine, and at the University of California, San Francisco in endocrinology and metabolism.
- Juergen Eckhardt
-
Juergen Eckhardt，自2020年9月起担任Metagenomi，Inc.董事会主席。Eckhardt博士自2019年2月起担任拜耳集团的Leaps负责人，此前曾于2016年9月至2019年2月担任风险投资负责人。他目前在Dewpoint Therapeutics、Khloris Biosciences、Oerth Bio以及其他几家私营生物技术公司和基金会的董事会任职。此前，Eckhardt博士曾在麦肯锡公司担任管理顾问和副合伙人，并在1994年至2002年期间担任麦肯锡医疗保健领导团队的成员。Eckhardt博士在巴塞尔大学获得医学博士学位，在法国枫丹白露的INSEAD获得MBA学位。
Juergen Eckhardt,has served as Chairman of the Board of Directors from September 2020 to February 2024. Dr. Eckhardt has served as Head of Leaps at Bayer AG since February 2019 and previously served as Head of Venture Investments from September 2016 to February 2019. He currently serves on the boards of Dewpoint Therapeutics, Khloris Biosciences, Oerth Bio, and a few other private biotechnology companies and foundations. Previously, Dr. Eckhardt served as a management consultant and Associate Partner at McKinsey & Co. and a member of McKinsey's Healthcare Leadership Team from 1994 to 2002. Dr. Eckhardt received his M.D. from the University of Basel and his M.B.A. from INSEAD in Fontainebleau, France. - Juergen Eckhardt，自2020年9月起担任Metagenomi，Inc.董事会主席。Eckhardt博士自2019年2月起担任拜耳集团的Leaps负责人，此前曾于2016年9月至2019年2月担任风险投资负责人。他目前在Dewpoint Therapeutics、Khloris Biosciences、Oerth Bio以及其他几家私营生物技术公司和基金会的董事会任职。此前，Eckhardt博士曾在麦肯锡公司担任管理顾问和副合伙人，并在1994年至2002年期间担任麦肯锡医疗保健领导团队的成员。Eckhardt博士在巴塞尔大学获得医学博士学位，在法国枫丹白露的INSEAD获得MBA学位。
- Juergen Eckhardt,has served as Chairman of the Board of Directors from September 2020 to February 2024. Dr. Eckhardt has served as Head of Leaps at Bayer AG since February 2019 and previously served as Head of Venture Investments from September 2016 to February 2019. He currently serves on the boards of Dewpoint Therapeutics, Khloris Biosciences, Oerth Bio, and a few other private biotechnology companies and foundations. Previously, Dr. Eckhardt served as a management consultant and Associate Partner at McKinsey & Co. and a member of McKinsey's Healthcare Leadership Team from 1994 to 2002. Dr. Eckhardt received his M.D. from the University of Basel and his M.B.A. from INSEAD in Fontainebleau, France.
- Brian C. Thomas
-
Brian C. Thomas是Metagenomi，Inc.创始人，自2016年9月起担任Metagenomi，Inc.首席执行官。自2022年12月起，Thomas博士担任Haya Therapeutics，Inc.的董事会主席。此前，从2001年到2017年，Thomas博士担任加州大学伯克利分校的项目经理。从1999年到2001年，Thomas博士在EOS生物技术公司（现为PDL，Inc.）担任首席生物信息学家。Thomas博士在堪萨斯大学获得细胞生物学学士学位和生物化学博士学位，并在加州大学伯克利分校完成了计算生物学的博士后研究。
Brian C. Thomas,is founder and has served as Chief Executive Officer since September 2016 and as Chairman of the Board since February 2024. Since December 2022, Dr. Thomas has served as Chairman of the Board of Directors of Haya Therapeutics, Inc. Previously, from 2001 to 2017, Dr. Thomas served as a program manager at University of California, Berkeley. From 1999 to 2001, Dr. Thomas served as a lead bioinformatics scientist at EOS Biotechnology (now PDL, Inc.). Dr. Thomas received his B.Sc. in cellular biology and his Ph.D. in biochemistry from University of Kansas and completed his post-doctoral research in computational biology at University of California, Berkeley. - Brian C. Thomas是Metagenomi，Inc.创始人，自2016年9月起担任Metagenomi，Inc.首席执行官。自2022年12月起，Thomas博士担任Haya Therapeutics，Inc.的董事会主席。此前，从2001年到2017年，Thomas博士担任加州大学伯克利分校的项目经理。从1999年到2001年，Thomas博士在EOS生物技术公司（现为PDL，Inc.）担任首席生物信息学家。Thomas博士在堪萨斯大学获得细胞生物学学士学位和生物化学博士学位，并在加州大学伯克利分校完成了计算生物学的博士后研究。
- Brian C. Thomas,is founder and has served as Chief Executive Officer since September 2016 and as Chairman of the Board since February 2024. Since December 2022, Dr. Thomas has served as Chairman of the Board of Directors of Haya Therapeutics, Inc. Previously, from 2001 to 2017, Dr. Thomas served as a program manager at University of California, Berkeley. From 1999 to 2001, Dr. Thomas served as a lead bioinformatics scientist at EOS Biotechnology (now PDL, Inc.). Dr. Thomas received his B.Sc. in cellular biology and his Ph.D. in biochemistry from University of Kansas and completed his post-doctoral research in computational biology at University of California, Berkeley.
- Jian Irish
-
Jian Irish，自2021年11月起担任Metagenomi，Inc.总裁，自2021年1月起担任Metagenomi，Inc.首席运营官。在加入Metagenomi，Inc.之前，Dr. Irish曾于2016年9月至2020年12月在Kite Pharma（现为吉利德的子公司）担任高级副总裁、全球制造主管和供应链高级副总裁等职务。爱尔兰博士于2021年1月至2022年1月期间担任Affini-T Therapeutics的临时首席运营官。Irish博士还于2018年10月至2020年4月期间担任复星Kite的临时首席技术官和董事会成员，该公司是Kite Pharma和复星医药的合资企业。2014年12月至2016年8月，Dr. Irish在赛诺菲担任生物制品供应、外包、合作伙伴关系和外部制造副总裁以及产品开发副总裁等职务。从2000年1月到2014年9月，Dr. Irish在安进担任过多个运营方面的领导职务，包括JAPAC Supply执行董事、Contract Manufacturing执行董事、麒麟-安进合资企业官员以及全球运营团队负责人。爱尔兰博士目前担任Ori Biotech、ORCA Biosystems和VITTORIA Biotherapeutics的顾问。爱尔兰博士获得华东理工大学化学工程学士学位，千叶大学制药科学硕士和博士学位，加州大学洛杉矶分校安德森管理学院MBA学位。
Jian Irish,has served as President since November 2021 and Chief Operating Officer since January 2021. Prior to joining Metagenomi, Inc. , Dr. Irish held positions as Senior Vice President, Global Head of Manufacturing and Senior Vice President of Supply Chain at Kite Pharma (now a subsidiary of Gilead) from September 2016 to December 2020. Dr. Irish served as Interim Chief Operating Officer of Affini-T Therapeutics from January 2021 to January 2022. Dr. Irish also served as Interim Chief Technology Officer and a board member for Fosun Kite, a joint venture between Kite Pharma and Fosun Pharma, from October 2018 to April 2020. From December 2014 to August 2016, Dr. Irish held positions as Vice President of Biologics Supply, Outsourcing, Partnerships, and External Manufacturing and Vice President of Product Development at Sanofi. From January 2000 to September 2014, Dr. Irish held various leadership positions at Amgen in operations, including Executive Director of JAPAC Supply, Executive Director of Contract Manufacturing, Officer for Kirin-Amgen JV, and Global Operations Team Leader. Dr. Irish currently serves as an advisor to Ori Biotech, and previously served as an advisor to ORCA Biosystems and ViTToria Biotherapeutics. Dr. Irish received a B.S. in chemical engineering from East China University of Science and Technology, an M.S. and Ph.D. in pharmaceutical sciences from Chiba University, and an M.B.A. from University of California, Los Angeles, Anderson School of Management. - Jian Irish，自2021年11月起担任Metagenomi，Inc.总裁，自2021年1月起担任Metagenomi，Inc.首席运营官。在加入Metagenomi，Inc.之前，Dr. Irish曾于2016年9月至2020年12月在Kite Pharma（现为吉利德的子公司）担任高级副总裁、全球制造主管和供应链高级副总裁等职务。爱尔兰博士于2021年1月至2022年1月期间担任Affini-T Therapeutics的临时首席运营官。Irish博士还于2018年10月至2020年4月期间担任复星Kite的临时首席技术官和董事会成员，该公司是Kite Pharma和复星医药的合资企业。2014年12月至2016年8月，Dr. Irish在赛诺菲担任生物制品供应、外包、合作伙伴关系和外部制造副总裁以及产品开发副总裁等职务。从2000年1月到2014年9月，Dr. Irish在安进担任过多个运营方面的领导职务，包括JAPAC Supply执行董事、Contract Manufacturing执行董事、麒麟-安进合资企业官员以及全球运营团队负责人。爱尔兰博士目前担任Ori Biotech、ORCA Biosystems和VITTORIA Biotherapeutics的顾问。爱尔兰博士获得华东理工大学化学工程学士学位，千叶大学制药科学硕士和博士学位，加州大学洛杉矶分校安德森管理学院MBA学位。
- Jian Irish,has served as President since November 2021 and Chief Operating Officer since January 2021. Prior to joining Metagenomi, Inc. , Dr. Irish held positions as Senior Vice President, Global Head of Manufacturing and Senior Vice President of Supply Chain at Kite Pharma (now a subsidiary of Gilead) from September 2016 to December 2020. Dr. Irish served as Interim Chief Operating Officer of Affini-T Therapeutics from January 2021 to January 2022. Dr. Irish also served as Interim Chief Technology Officer and a board member for Fosun Kite, a joint venture between Kite Pharma and Fosun Pharma, from October 2018 to April 2020. From December 2014 to August 2016, Dr. Irish held positions as Vice President of Biologics Supply, Outsourcing, Partnerships, and External Manufacturing and Vice President of Product Development at Sanofi. From January 2000 to September 2014, Dr. Irish held various leadership positions at Amgen in operations, including Executive Director of JAPAC Supply, Executive Director of Contract Manufacturing, Officer for Kirin-Amgen JV, and Global Operations Team Leader. Dr. Irish currently serves as an advisor to Ori Biotech, and previously served as an advisor to ORCA Biosystems and ViTToria Biotherapeutics. Dr. Irish received a B.S. in chemical engineering from East China University of Science and Technology, an M.S. and Ph.D. in pharmaceutical sciences from Chiba University, and an M.B.A. from University of California, Los Angeles, Anderson School of Management.
- Eric Bjerkholt
-
Eric Bjerkholt，自2025年1月起担任董事会董事。Bjerkholt先生自2023年9月起担任Mirum Pharmaceuticals, Inc.（一家开发孤儿和罕见疾病治疗方法的生物制药公司）的首席财务官。在此之前，Bjerkholt先生于2020年11月至2023年8月在专注于肾脏疾病的生物制药公司Chinook Therapeutics, Inc.担任首席财务官。2023年8月，Chinook Therapeutics被诺华制药（Novartis AG）收购。在加入Chinook Therapeutics, Inc.之前，他于2017年4月至2020年11月期间担任开发食物过敏治疗方法的生物技术公司Aimmune治疗公司的首席财务官，此时Aimmune被Nestle Health Science US Holdings，Inc.收购。在加入Aimmune治疗之前，Bjerkholt先生从2004年到2017年在Sunesis Pharmaceuticals，Inc.工作了13年，Bjerkholt先生除了担任首席财务官之外，还担任过多种职务，包括企业发展和财务执行副总裁、公司秘书和首席合规官。在此之前，Bjerkholt先生曾在IntraBiotics Pharmaceuticals，Inc.、LifeSpring Nutrition，Inc.和Age Wave，LLC担任高级管理财务职务，并在J.P. Morgan & Company，Inc.从事了七年的医疗保健投资银行工作。他目前是上市生物技术公司Surrozen, Inc.的董事会成员，以及上市生物技术公司Cerus Corporation的董事会成员。Bjerkholt先生曾于2020年9月至2025年1月担任上市生物技术公司CalciMedica，Inc.的董事会成员和审计委员会主席。Bjerkholt先生持有一只蜡烛。挪威奥斯陆大学经济学oecon学位，哈佛商学院工商管理硕士。
Eric Bjerkholt,has served on board of directors since January 2025. Mr. Bjerkholt has served as the Chief Financial Officer of Mirum Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for orphan and rare diseases, since September 2023. Prior to that, Mr. Bjerkholt served as Chief Financial Officer of Chinook Therapeutics, Inc., a biopharmaceutical company focused on kidney diseases, from November 2020 to August 2023. In August 2023, Chinook Therapeutics was acquired by Novartis AG. Before Chinook Therapeutics, Inc., he served as the Chief Financial Officer of Aimmune Therapeutics, Inc., a biotechnology company developing treatments for food allergies, from April 2017 to November 2020, at which time, Aimmune was acquired by Nestle Health Science US Holdings, Inc. Prior to Aimmune Therapeutics, Mr. Bjerkholt spent 13 years at Sunesis Pharmaceuticals, Inc. from 2004 until 2017, where in addition to his role as Chief Financial Officer, Mr. Bjerkholt served in various capacities, including Executive Vice President of Corporate Development and Finance, Corporate Secretary and Chief Compliance Officer. Previously, Mr. Bjerkholt held senior executive finance roles at IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc. and Age Wave, LLC and spent seven years in healthcare investment banking at J.P. Morgan & Company, Inc. He is currently a member of the board of directors of Surrozen, Inc., a publicly traded biotechnology company, and a member of the board of directors of Cerus Corporation, a publicly traded biotechnology company. Mr. Bjerkholt previously served as a member of the board of directors and Chair of the audit committee of CalciMedica, Inc., a publicly traded biotechnology company, from September 2020 until January 2025. Mr. Bjerkholt holds a Cand. Oecon degree in economics from the University of Oslo in Norway and an M.B.A. from Harvard Business School. - Eric Bjerkholt，自2025年1月起担任董事会董事。Bjerkholt先生自2023年9月起担任Mirum Pharmaceuticals, Inc.（一家开发孤儿和罕见疾病治疗方法的生物制药公司）的首席财务官。在此之前，Bjerkholt先生于2020年11月至2023年8月在专注于肾脏疾病的生物制药公司Chinook Therapeutics, Inc.担任首席财务官。2023年8月，Chinook Therapeutics被诺华制药（Novartis AG）收购。在加入Chinook Therapeutics, Inc.之前，他于2017年4月至2020年11月期间担任开发食物过敏治疗方法的生物技术公司Aimmune治疗公司的首席财务官，此时Aimmune被Nestle Health Science US Holdings，Inc.收购。在加入Aimmune治疗之前，Bjerkholt先生从2004年到2017年在Sunesis Pharmaceuticals，Inc.工作了13年，Bjerkholt先生除了担任首席财务官之外，还担任过多种职务，包括企业发展和财务执行副总裁、公司秘书和首席合规官。在此之前，Bjerkholt先生曾在IntraBiotics Pharmaceuticals，Inc.、LifeSpring Nutrition，Inc.和Age Wave，LLC担任高级管理财务职务，并在J.P. Morgan & Company，Inc.从事了七年的医疗保健投资银行工作。他目前是上市生物技术公司Surrozen, Inc.的董事会成员，以及上市生物技术公司Cerus Corporation的董事会成员。Bjerkholt先生曾于2020年9月至2025年1月担任上市生物技术公司CalciMedica，Inc.的董事会成员和审计委员会主席。Bjerkholt先生持有一只蜡烛。挪威奥斯陆大学经济学oecon学位，哈佛商学院工商管理硕士。
- Eric Bjerkholt,has served on board of directors since January 2025. Mr. Bjerkholt has served as the Chief Financial Officer of Mirum Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for orphan and rare diseases, since September 2023. Prior to that, Mr. Bjerkholt served as Chief Financial Officer of Chinook Therapeutics, Inc., a biopharmaceutical company focused on kidney diseases, from November 2020 to August 2023. In August 2023, Chinook Therapeutics was acquired by Novartis AG. Before Chinook Therapeutics, Inc., he served as the Chief Financial Officer of Aimmune Therapeutics, Inc., a biotechnology company developing treatments for food allergies, from April 2017 to November 2020, at which time, Aimmune was acquired by Nestle Health Science US Holdings, Inc. Prior to Aimmune Therapeutics, Mr. Bjerkholt spent 13 years at Sunesis Pharmaceuticals, Inc. from 2004 until 2017, where in addition to his role as Chief Financial Officer, Mr. Bjerkholt served in various capacities, including Executive Vice President of Corporate Development and Finance, Corporate Secretary and Chief Compliance Officer. Previously, Mr. Bjerkholt held senior executive finance roles at IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc. and Age Wave, LLC and spent seven years in healthcare investment banking at J.P. Morgan & Company, Inc. He is currently a member of the board of directors of Surrozen, Inc., a publicly traded biotechnology company, and a member of the board of directors of Cerus Corporation, a publicly traded biotechnology company. Mr. Bjerkholt previously served as a member of the board of directors and Chair of the audit committee of CalciMedica, Inc., a publicly traded biotechnology company, from September 2020 until January 2025. Mr. Bjerkholt holds a Cand. Oecon degree in economics from the University of Oslo in Norway and an M.B.A. from Harvard Business School.
- Eric Bjerkholt
-
Eric Bjerkholt2004年3月被选为董事会成员。他是一家生物制药公司Sunesis Pharmaceuticals股份有限公司的执行副总裁兼首席财务官。Bjerkholt先生是 Round Table Pizza公司的董事会一员。
Eric Bjerkholt,has served as a member of Graybug's board of directors since September 2020. Since November 2020, Mr. Bjerkholt has been the Chief Financial Officer of Chinook Therapeutics, Inc., a biotechnology company developing treatments for kidney diseases. From April 2017 to November 2020, Mr. Bjerkholt served as the Chief Financial Officer of Aimmune Therapeutics, Inc., a biotechnology company developing treatments for food allergies. From 2004 until April 2017, Mr. Bjerkholt held various roles at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company developing oncology therapeutics, including as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From 2002 to 2004, he was Senior Vice President and Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Ardea Biosciences, Inc. in 2006. Mr. Bjerkholt was a co-founder of LifeSpring Nutrition, Inc., a nutraceutical company, and from 1999 to 2002 served at various times as its Chief Executive Officer, President, and Chief Financial Officer. From 1990 to 1997, he also served as a vice president in the healthcare banking group at J.P. Morgan & Co. Incorporated, an international banking firm. He has served on the boards of directors of several publicly traded companies, including as a member of the board of directors and chair of the audit committee of Corium, Inc. until its acquisition by Gurnet Point Capital in November 2018, and as a member of the board of directors and as chair of the audit committee of StemCells, a biotechnology company, until its November 2016 acquisition by Microbot Medical Ltd. He currently is a member of the board of directors of Cerus Corporation, a biotechnology company. He holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School. - Eric Bjerkholt2004年3月被选为董事会成员。他是一家生物制药公司Sunesis Pharmaceuticals股份有限公司的执行副总裁兼首席财务官。Bjerkholt先生是 Round Table Pizza公司的董事会一员。
- Eric Bjerkholt,has served as a member of Graybug's board of directors since September 2020. Since November 2020, Mr. Bjerkholt has been the Chief Financial Officer of Chinook Therapeutics, Inc., a biotechnology company developing treatments for kidney diseases. From April 2017 to November 2020, Mr. Bjerkholt served as the Chief Financial Officer of Aimmune Therapeutics, Inc., a biotechnology company developing treatments for food allergies. From 2004 until April 2017, Mr. Bjerkholt held various roles at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company developing oncology therapeutics, including as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From 2002 to 2004, he was Senior Vice President and Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Ardea Biosciences, Inc. in 2006. Mr. Bjerkholt was a co-founder of LifeSpring Nutrition, Inc., a nutraceutical company, and from 1999 to 2002 served at various times as its Chief Executive Officer, President, and Chief Financial Officer. From 1990 to 1997, he also served as a vice president in the healthcare banking group at J.P. Morgan & Co. Incorporated, an international banking firm. He has served on the boards of directors of several publicly traded companies, including as a member of the board of directors and chair of the audit committee of Corium, Inc. until its acquisition by Gurnet Point Capital in November 2018, and as a member of the board of directors and as chair of the audit committee of StemCells, a biotechnology company, until its November 2016 acquisition by Microbot Medical Ltd. He currently is a member of the board of directors of Cerus Corporation, a biotechnology company. He holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Sarah Noonberg
Sarah Noonberg自2017年12月起担任董事会成员。自2019年5月以来，Noonberg博士为多家私人生物技术公司提供首席医疗官顾问服务。她此前曾于2018年5月至2019年5月担任Nohla Therapeutics的首席医疗官，Nohla Therapeutics是用于血液系统恶性肿瘤和其他危重疾病患者的通用现成细胞疗法的开发商。在加入Nohla Therapeutics之前，她曾于2017年5月至2018年3月担任生物技术公司Prothena Corporation plc的首席医疗官。在加入Prothena之前，Noonberg博士于2015年8月至2017年3月担任生物技术公司BioMarin Pharmaceuticals Inc.的集团Vice President兼全球临床开发主管，负责多个临床产品组合的开发战略和执行。从2007年到2015年8月，她在生物制药公司Medivation，Inc.担任过多个职位，在那里，作为早期开发的高级副总裁和临床开发的Vice President，她领导了各个开发阶段的项目，包括恩扎鲁他胺Xtandi用于治疗化疗-Na&239；ve转移性前列腺癌。她也曾担任Chiron Corporation的一些临床职务（2004年至2007年），在那里她曾领导传染病和肺部适应症化合物的临床开发。她自2019年8月起担任公共生物制药公司Neoleukin Therapeutics的董事会成员。Noonberg博士在加州大学旧金山分校（University of California，San Francisco）获得医学博士学位，在加州大学伯克利分校（University of California，Berkeley）获得生物工程博士学位，在达特茅斯学院（Dartmouth College）获得理学学士学位。她是董事会认证的内科医生，并完成了Johns Hopkins Hospital的住院医师资格。从2002年到2018年，她是一名兼职住院医师，担任主治医生，治疗广泛的住院和危重病人。
Sarah Noonberg,has served as Chief Medical Officer since January 2023. Prior to joining Metagenomi, Inc. , Dr. Noonberg served as the Chief Medical Officer at Maze Therapeutics, Nohla Therapeutics and Prothena Corporation plc (Nasdaq: PRTA) from July 2020 to September 2022, May 2018 to May 2019 and May 2017 to May 2018, respectively. Dr. Noonberg served as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc. (Nasdaq: BMRN) from August 2015 to March 2017. From May 2007 to August 2015, she held several positions at Medivation, Inc., a biopharmaceutical company, culminating in the position of Senior Vice President of Early Development. Dr. Noonberg currently serves on the board of directors of Neurogene Inc. (Nasdaq: NGNE). She has also previously served on the board of directors of Neoleukin Therapeutics (Nasdaq: NLTX) from August 2019 to December 2023, Protagonist Therapeutics, Inc. (Nasdaq: PTGX) from December 2017 to May 2023, and Marinus Pharmaceuticals (Nasdaq: MRNS) from May 2023 to November 2024. Dr. Noonberg received her B.S. in engineering at Dartmouth College, her Ph.D. in bioengineering from the University of California, Berkeley and her M.D. from the University of California, San Francisco. Dr. Noonberg is a board-certified internist and completed her residency at Johns Hopkins Hospital.- Sarah Noonberg自2017年12月起担任董事会成员。自2019年5月以来，Noonberg博士为多家私人生物技术公司提供首席医疗官顾问服务。她此前曾于2018年5月至2019年5月担任Nohla Therapeutics的首席医疗官，Nohla Therapeutics是用于血液系统恶性肿瘤和其他危重疾病患者的通用现成细胞疗法的开发商。在加入Nohla Therapeutics之前，她曾于2017年5月至2018年3月担任生物技术公司Prothena Corporation plc的首席医疗官。在加入Prothena之前，Noonberg博士于2015年8月至2017年3月担任生物技术公司BioMarin Pharmaceuticals Inc.的集团Vice President兼全球临床开发主管，负责多个临床产品组合的开发战略和执行。从2007年到2015年8月，她在生物制药公司Medivation，Inc.担任过多个职位，在那里，作为早期开发的高级副总裁和临床开发的Vice President，她领导了各个开发阶段的项目，包括恩扎鲁他胺Xtandi用于治疗化疗-Na&239；ve转移性前列腺癌。她也曾担任Chiron Corporation的一些临床职务（2004年至2007年），在那里她曾领导传染病和肺部适应症化合物的临床开发。她自2019年8月起担任公共生物制药公司Neoleukin Therapeutics的董事会成员。Noonberg博士在加州大学旧金山分校（University of California，San Francisco）获得医学博士学位，在加州大学伯克利分校（University of California，Berkeley）获得生物工程博士学位，在达特茅斯学院（Dartmouth College）获得理学学士学位。她是董事会认证的内科医生，并完成了Johns Hopkins Hospital的住院医师资格。从2002年到2018年，她是一名兼职住院医师，担任主治医生，治疗广泛的住院和危重病人。
- Sarah Noonberg,has served as Chief Medical Officer since January 2023. Prior to joining Metagenomi, Inc. , Dr. Noonberg served as the Chief Medical Officer at Maze Therapeutics, Nohla Therapeutics and Prothena Corporation plc (Nasdaq: PRTA) from July 2020 to September 2022, May 2018 to May 2019 and May 2017 to May 2018, respectively. Dr. Noonberg served as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc. (Nasdaq: BMRN) from August 2015 to March 2017. From May 2007 to August 2015, she held several positions at Medivation, Inc., a biopharmaceutical company, culminating in the position of Senior Vice President of Early Development. Dr. Noonberg currently serves on the board of directors of Neurogene Inc. (Nasdaq: NGNE). She has also previously served on the board of directors of Neoleukin Therapeutics (Nasdaq: NLTX) from August 2019 to December 2023, Protagonist Therapeutics, Inc. (Nasdaq: PTGX) from December 2017 to May 2023, and Marinus Pharmaceuticals (Nasdaq: MRNS) from May 2023 to November 2024. Dr. Noonberg received her B.S. in engineering at Dartmouth College, her Ph.D. in bioengineering from the University of California, Berkeley and her M.D. from the University of California, San Francisco. Dr. Noonberg is a board-certified internist and completed her residency at Johns Hopkins Hospital.
- Brian C. Thomas
Brian C. Thomas是Metagenomi，Inc.创始人，自2016年9月起担任Metagenomi，Inc.首席执行官。自2022年12月起，Thomas博士担任Haya Therapeutics，Inc.的董事会主席。此前，从2001年到2017年，Thomas博士担任加州大学伯克利分校的项目经理。从1999年到2001年，Thomas博士在EOS生物技术公司（现为PDL，Inc.）担任首席生物信息学家。Thomas博士在堪萨斯大学获得细胞生物学学士学位和生物化学博士学位，并在加州大学伯克利分校完成了计算生物学的博士后研究。
Brian C. Thomas,is founder and has served as Chief Executive Officer since September 2016 and as Chairman of the Board since February 2024. Since December 2022, Dr. Thomas has served as Chairman of the Board of Directors of Haya Therapeutics, Inc. Previously, from 2001 to 2017, Dr. Thomas served as a program manager at University of California, Berkeley. From 1999 to 2001, Dr. Thomas served as a lead bioinformatics scientist at EOS Biotechnology (now PDL, Inc.). Dr. Thomas received his B.Sc. in cellular biology and his Ph.D. in biochemistry from University of Kansas and completed his post-doctoral research in computational biology at University of California, Berkeley.- Brian C. Thomas是Metagenomi，Inc.创始人，自2016年9月起担任Metagenomi，Inc.首席执行官。自2022年12月起，Thomas博士担任Haya Therapeutics，Inc.的董事会主席。此前，从2001年到2017年，Thomas博士担任加州大学伯克利分校的项目经理。从1999年到2001年，Thomas博士在EOS生物技术公司（现为PDL，Inc.）担任首席生物信息学家。Thomas博士在堪萨斯大学获得细胞生物学学士学位和生物化学博士学位，并在加州大学伯克利分校完成了计算生物学的博士后研究。
- Brian C. Thomas,is founder and has served as Chief Executive Officer since September 2016 and as Chairman of the Board since February 2024. Since December 2022, Dr. Thomas has served as Chairman of the Board of Directors of Haya Therapeutics, Inc. Previously, from 2001 to 2017, Dr. Thomas served as a program manager at University of California, Berkeley. From 1999 to 2001, Dr. Thomas served as a lead bioinformatics scientist at EOS Biotechnology (now PDL, Inc.). Dr. Thomas received his B.Sc. in cellular biology and his Ph.D. in biochemistry from University of Kansas and completed his post-doctoral research in computational biology at University of California, Berkeley.
- Jian Irish
Jian Irish，自2021年11月起担任Metagenomi，Inc.总裁，自2021年1月起担任Metagenomi，Inc.首席运营官。在加入Metagenomi，Inc.之前，Dr. Irish曾于2016年9月至2020年12月在Kite Pharma（现为吉利德的子公司）担任高级副总裁、全球制造主管和供应链高级副总裁等职务。爱尔兰博士于2021年1月至2022年1月期间担任Affini-T Therapeutics的临时首席运营官。Irish博士还于2018年10月至2020年4月期间担任复星Kite的临时首席技术官和董事会成员，该公司是Kite Pharma和复星医药的合资企业。2014年12月至2016年8月，Dr. Irish在赛诺菲担任生物制品供应、外包、合作伙伴关系和外部制造副总裁以及产品开发副总裁等职务。从2000年1月到2014年9月，Dr. Irish在安进担任过多个运营方面的领导职务，包括JAPAC Supply执行董事、Contract Manufacturing执行董事、麒麟-安进合资企业官员以及全球运营团队负责人。爱尔兰博士目前担任Ori Biotech、ORCA Biosystems和VITTORIA Biotherapeutics的顾问。爱尔兰博士获得华东理工大学化学工程学士学位，千叶大学制药科学硕士和博士学位，加州大学洛杉矶分校安德森管理学院MBA学位。
Jian Irish,has served as President since November 2021 and Chief Operating Officer since January 2021. Prior to joining Metagenomi, Inc. , Dr. Irish held positions as Senior Vice President, Global Head of Manufacturing and Senior Vice President of Supply Chain at Kite Pharma (now a subsidiary of Gilead) from September 2016 to December 2020. Dr. Irish served as Interim Chief Operating Officer of Affini-T Therapeutics from January 2021 to January 2022. Dr. Irish also served as Interim Chief Technology Officer and a board member for Fosun Kite, a joint venture between Kite Pharma and Fosun Pharma, from October 2018 to April 2020. From December 2014 to August 2016, Dr. Irish held positions as Vice President of Biologics Supply, Outsourcing, Partnerships, and External Manufacturing and Vice President of Product Development at Sanofi. From January 2000 to September 2014, Dr. Irish held various leadership positions at Amgen in operations, including Executive Director of JAPAC Supply, Executive Director of Contract Manufacturing, Officer for Kirin-Amgen JV, and Global Operations Team Leader. Dr. Irish currently serves as an advisor to Ori Biotech, and previously served as an advisor to ORCA Biosystems and ViTToria Biotherapeutics. Dr. Irish received a B.S. in chemical engineering from East China University of Science and Technology, an M.S. and Ph.D. in pharmaceutical sciences from Chiba University, and an M.B.A. from University of California, Los Angeles, Anderson School of Management.- Jian Irish，自2021年11月起担任Metagenomi，Inc.总裁，自2021年1月起担任Metagenomi，Inc.首席运营官。在加入Metagenomi，Inc.之前，Dr. Irish曾于2016年9月至2020年12月在Kite Pharma（现为吉利德的子公司）担任高级副总裁、全球制造主管和供应链高级副总裁等职务。爱尔兰博士于2021年1月至2022年1月期间担任Affini-T Therapeutics的临时首席运营官。Irish博士还于2018年10月至2020年4月期间担任复星Kite的临时首席技术官和董事会成员，该公司是Kite Pharma和复星医药的合资企业。2014年12月至2016年8月，Dr. Irish在赛诺菲担任生物制品供应、外包、合作伙伴关系和外部制造副总裁以及产品开发副总裁等职务。从2000年1月到2014年9月，Dr. Irish在安进担任过多个运营方面的领导职务，包括JAPAC Supply执行董事、Contract Manufacturing执行董事、麒麟-安进合资企业官员以及全球运营团队负责人。爱尔兰博士目前担任Ori Biotech、ORCA Biosystems和VITTORIA Biotherapeutics的顾问。爱尔兰博士获得华东理工大学化学工程学士学位，千叶大学制药科学硕士和博士学位，加州大学洛杉矶分校安德森管理学院MBA学位。
- Jian Irish,has served as President since November 2021 and Chief Operating Officer since January 2021. Prior to joining Metagenomi, Inc. , Dr. Irish held positions as Senior Vice President, Global Head of Manufacturing and Senior Vice President of Supply Chain at Kite Pharma (now a subsidiary of Gilead) from September 2016 to December 2020. Dr. Irish served as Interim Chief Operating Officer of Affini-T Therapeutics from January 2021 to January 2022. Dr. Irish also served as Interim Chief Technology Officer and a board member for Fosun Kite, a joint venture between Kite Pharma and Fosun Pharma, from October 2018 to April 2020. From December 2014 to August 2016, Dr. Irish held positions as Vice President of Biologics Supply, Outsourcing, Partnerships, and External Manufacturing and Vice President of Product Development at Sanofi. From January 2000 to September 2014, Dr. Irish held various leadership positions at Amgen in operations, including Executive Director of JAPAC Supply, Executive Director of Contract Manufacturing, Officer for Kirin-Amgen JV, and Global Operations Team Leader. Dr. Irish currently serves as an advisor to Ori Biotech, and previously served as an advisor to ORCA Biosystems and ViTToria Biotherapeutics. Dr. Irish received a B.S. in chemical engineering from East China University of Science and Technology, an M.S. and Ph.D. in pharmaceutical sciences from Chiba University, and an M.B.A. from University of California, Los Angeles, Anderson School of Management.
- Pamela Wapnick
Pamela Wapnick，自2023年9月起担任Metagenomi，Inc. 首席财务官。在加入Metagenomi，Inc.之前，Wapnick女士于2022年6月至2023年9月担任Diality Inc.的首席财务官，于2019年11月至2022年6月担任Capsida Biotherapeutics的首席财务官，并于2017年12月至2019年10月担任Graybug Vision的首席财务官。在担任这些职务之前，Wapnick女士曾担任True North Therapeutics的首席财务官，并曾在安进公司（AMGN）担任多个职位。Wapnick女士获得了韦尔斯利学院的经济学学士学位和哥伦比亚商学院的金融MBA学位。
Pamela Wapnick,has served as Chief Financial Officer since September 2023. Prior to joining Metagenomi, Inc. , Ms. Wapnick served as Chief Financial Officer of Diality Inc. from June 2022 to September 2023, as Chief Financial Officer of Capsida Biotherapeutics from November 2019 to June 2022, and as Chief Financial Officer of Graybug Vision from December 2017 to October 2019. Prior to these roles, Ms. Wapnick served as Chief Financial Officer of True North Therapeutics and held various positions at Amgen Inc. (Nasdaq: AMGN). Ms. Wapnick received her B.A. in economics from Wellesley College and her M.B.A. in finance from Columbia Business School.- Pamela Wapnick，自2023年9月起担任Metagenomi，Inc. 首席财务官。在加入Metagenomi，Inc.之前，Wapnick女士于2022年6月至2023年9月担任Diality Inc.的首席财务官，于2019年11月至2022年6月担任Capsida Biotherapeutics的首席财务官，并于2017年12月至2019年10月担任Graybug Vision的首席财务官。在担任这些职务之前，Wapnick女士曾担任True North Therapeutics的首席财务官，并曾在安进公司（AMGN）担任多个职位。Wapnick女士获得了韦尔斯利学院的经济学学士学位和哥伦比亚商学院的金融MBA学位。
- Pamela Wapnick,has served as Chief Financial Officer since September 2023. Prior to joining Metagenomi, Inc. , Ms. Wapnick served as Chief Financial Officer of Diality Inc. from June 2022 to September 2023, as Chief Financial Officer of Capsida Biotherapeutics from November 2019 to June 2022, and as Chief Financial Officer of Graybug Vision from December 2017 to October 2019. Prior to these roles, Ms. Wapnick served as Chief Financial Officer of True North Therapeutics and held various positions at Amgen Inc. (Nasdaq: AMGN). Ms. Wapnick received her B.A. in economics from Wellesley College and her M.B.A. in finance from Columbia Business School.
- Matthew L. Wein
Matthew L. Wein，自2024年2月起担任Metagenomi，Inc.公司法律和合规副总裁，公司秘书。最近，Wein先生于2021年9月至2023年12月担任Mustang Bio, Inc.（纳斯达克：MBIO）的总法律顾问和公司秘书。在加入Mustang之前，Wein先生曾于2016年6月至2021年8月期间担任赛诺菲全球战略和联盟管理高级总监；并于2002年9月至2016年5月期间担任安进公司（AMGN）的高级法律顾问。Wein先生于1999年8月至2002年8月期间担任Arter & Haden LLP的助理律师。Wein先生获得了卫斯理大学的学士学位和南加州大学法学院的法学博士学位。Wein先生获准在加利福尼亚州和马萨诸塞州从事法律业务。
Matthew L. Wein,has served as Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary since February 2025 and previously served as Vice President of Corporate Legal, Compliance and Corporate Secretary from February 2024 to February 2025. Prior to Metagenomi, Mr. Wein served as General Counsel and Corporate Secretary of Mustang Bio, Inc. (Nasdaq: MBIO) from September 2021 to December 2023. Mr. Wein held various roles as Senior Director in global strategy and alliance management for Sanofi between June 2016 and August 2021; and as Senior Counsel at Amgen Inc. (Nasdaq: AMGN) from September 2002 to May 2016. Mr. Wein was an associate attorney at Arter & Haden LLP from August 1999 to August 2002. Mr. Wein received his B.A. from Wesleyan University and his J.D. from University of Southern California Law School. Mr. Wein is admitted to practice law in California and Massachusetts.- Matthew L. Wein，自2024年2月起担任Metagenomi，Inc.公司法律和合规副总裁，公司秘书。最近，Wein先生于2021年9月至2023年12月担任Mustang Bio, Inc.（纳斯达克：MBIO）的总法律顾问和公司秘书。在加入Mustang之前，Wein先生曾于2016年6月至2021年8月期间担任赛诺菲全球战略和联盟管理高级总监；并于2002年9月至2016年5月期间担任安进公司（AMGN）的高级法律顾问。Wein先生于1999年8月至2002年8月期间担任Arter & Haden LLP的助理律师。Wein先生获得了卫斯理大学的学士学位和南加州大学法学院的法学博士学位。Wein先生获准在加利福尼亚州和马萨诸塞州从事法律业务。
- Matthew L. Wein,has served as Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary since February 2025 and previously served as Vice President of Corporate Legal, Compliance and Corporate Secretary from February 2024 to February 2025. Prior to Metagenomi, Mr. Wein served as General Counsel and Corporate Secretary of Mustang Bio, Inc. (Nasdaq: MBIO) from September 2021 to December 2023. Mr. Wein held various roles as Senior Director in global strategy and alliance management for Sanofi between June 2016 and August 2021; and as Senior Counsel at Amgen Inc. (Nasdaq: AMGN) from September 2002 to May 2016. Mr. Wein was an associate attorney at Arter & Haden LLP from August 1999 to August 2002. Mr. Wein received his B.A. from Wesleyan University and his J.D. from University of Southern California Law School. Mr. Wein is admitted to practice law in California and Massachusetts.